Login / Signup

One-carbon unit supplementation fuels tumor-infiltrating T cells and augments checkpoint blockade.

Xincheng XuZihong ChenCaroline R BartmanXi XingKellen OlszewskiJoshua D Rabinowitz
Published in: bioRxiv : the preprint server for biology (2023)
Checkpoint blockade has revolutionized cancer therapy. Durable tumor control, however, is achieved in only a minority of patients. We show that the efficacy of anti-PD-1 blockade can be enhanced by metabolic supplementation with one-carbon donors. Such donors support nucleotide synthesis in tumor-infiltrating T cells and merit future clinical evaluation.
Keyphrases
  • clinical evaluation
  • cancer therapy
  • dna damage
  • end stage renal disease
  • cell cycle
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • drug delivery
  • kidney transplantation
  • current status